SALT LAKE CITY — Denali Therapeutics is advancing the fight against neurodegenerative diseases thanks to pioneering work in methods to carry medicines across the blood-brain barrier, a critical ...

Denali Therapeutics Inc. (DNLI) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.50 per share a year ago.

A Denali Therapeutics drug for the rare enzyme deficiency Hunter syndrome is still in pivotal testing, but the company has guidance from the FDA on a pathway to get this therapy to the market sooner.

Feb 16 (Reuters) - Drug developer Denali Therapeutics (DNLI.O), opens new tab said on Friday its and partner Sanofi's (SASY.PA), opens new tab experimental drug for a fatal neurodegenerative ...